Candel Therapeutics CEO Paul FMedSci's 2023 pay slips 20% to $1.5M
Candel Therapeutics reports 2023 executive compensation
By ExecPay News
Published: May 30, 2024
Candel Therapeutics reported fiscal year 2023 executive compensation information on May 30, 2024.
In 2023, three executives at Candel Therapeutics received on average a compensation package of $961K, a 21% decrease compared to previous year.
Average pay of disclosed executives at Candel Therapeutics
Paul Peter Tak, M.D., Ph.D., FMedSci, Chief Executive Officer, received $1.5M in total, which decreased by 20% compared to 2022. 45% of FMedSci's compensation, or $670K, was in salary. FMedSci also received $134K in non-equity incentive plan, $190K in option awards, $177K in stock awards, as well as $315K in other compensation.
Francesca Barone, Chief Scientific Officer, received a compensation package of $707K, which decreased by 22% compared to previous year. 58% of the compensation package, or $413K, was in salary.
Jason A. Amello, Chief Financial Officer, earned $692K in 2023.
Related executives
You may also like
Source: SEC filing on May 30, 2024.